Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BETTER-B: Better Treatments for Refractory Breathlessness
ISRCTN10487976Phase 3Completed
- Sponsor
- King's College London
- Start
- Feb 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Chronic breathlessness syndrome comparing Mirtazapine with Placebo (2 arms). Primary endpoint: Worst breathlessness over the past 24 hours at day 56. Started Feb 2021; status: completed.
02
Drugs
mirtazapine
03
Conditions
Chronic breathlessness syndrome
Beyond the preview
Go deeper on ISRCTN10487976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10487976.